NY-INCUBETA
12.4.2021 11:03:04 CEST | Business Wire | Press release
Leading digital marketing group, Incubeta today announces its new brand identity which unites its specialist teams under one Incubeta brand. The launch of the new positioning is aligned with Incubeta’s emphasis on helping businesses to upgrade their growth through creativity, collaboration and expertise. This rebrand reinforces its commitment to being true performance partners, helping businesses find the right opportunities to accelerate growth.
This vibrant new look for Incubeta represents the personality of the fun, diverse, bright and exciting team that make up the company. A team of more than 440 creators, thinkers, makers, and doers obsessed with finding creative ways to take businesses further, faster. Incubeta’s ‘Upgrade your Growth’ narrative emphasises how the business will grow alongside its clients focusing on expanding its services and products across the entire customer journey, giving clients back control over their data, customers and actions. The Incubeta group has grown 20 fold over the past 7 years, offering fantastic growth opportunities for its people and helping its rising number of clients grow in a complex digital environment.
The unification of its specialisms will ensure Incubeta remains at the forefront of innovation to help businesses unlock the power of digital and amplify growth. It will also position the company as the new generation of digital growth partner – transparent, accountable and agile. Incubeta applies the technical, strategic and creative expertise to help businesses connect with customers, improve performance and extend reach – all in the service of growth.
Lars Lehne, Group CEO of Incubeta comments: “We are thrilled to unveil this new positioning representing the next chapter in our own growth story. Knocking down the silos of marketing and bringing our specialist teams together to build world-class solutions, helps our clients and partners deliver meaningful growth. While the Incubeta family will have a different look, what won’t change is the quality of our services and commitment to delivering outstanding work.”
Incubeta was founded in 2011 when the company Interface made the reverse acquisition of IncuBeta Holdings. It now operates across 17 countries with offices in most major cities across the world. In 2013 the highly successful Net Media Planet (NMPi) was acquired and in 2016 the subsequent acquisition of DQ&A extended the company’s geographical and product growth. This was followed by the acquisition of creative specialists Joystick in 2018 and most recently ecommerce experts Groundswell in March 2021. Today, some of the most innovative brands work with Incubeta, including Google, Amazon, Disney, HBO, Charlotte Tilbury, L'Oréal and Zalando.
ENDS
About Incubeta:
Incubeta is a team of over 440 creators, thinkers, makers and doers working across 17 offices globally to unlock business growth for clients including Google, Hyundai, Netflix, HBO and L'Oréal. Incubeta combines capabilities across the full spectrum of digital disciplines to deliver standout outcomes at every brand touchpoint, from awareness to fulfilment.
Find out more at: incubeta.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005054/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom